ECRI Institute and Data Leverage Group Collaborate to Streamline Healthcare Value Analysis

ECRI Institute, a nonprofit that researches the best approaches to patient care, announces a new agreement with Data Leverage Group, which specializes in value analysis workflow solutions for hospitals and health systems.

Through this agreement, ECRI Institute’s unbiased, evidence-based clinical, cost, reimbursement, and safety data will be incorporated into product request workflows for surgical supplies and physician preference items, including implants, in Data Leverage Group member hospitals.

“ECRI Institute’s alliance with Data Leverage Group will give their clients quicker access to high-quality data, which relieves them of the time-consuming research that’s required of hospitals to make the best decisions they possibly can on the products they’re considering,” says Timothy Browne, director, ECRI Institute.

Data Leverage Group’s Value Analysis Management Software System® (VAMS®) supports healthcare organizations in the management of their value analysis processes.

“Simplification and alignment of our customers’ value analysis processes have always been part of our mission. This collaboration makes it easy for value analysis professionals to seamlessly connect their clinical evidence due diligence efforts with their internal value analysis implementation processes. This partnership keeps our clients focused on their mission: to select only the products that will enhance their bottom line and improve patient care,” says Stephen B. Kinsella, president, Data Leverage Group, LLC.

With a wide-ranging spectrum of available data on surgical supplies and physician preference items, including implants, ECRI Institute will make its published data fully accessible for members of Data Leverage Group. They will also have the opportunity to request custom, product-specific research.

To learn more about this agreement or ECRI Institute’s value analysis services, visit www.ecri.org/valueguide; or contact Timothy Browne by telephone at (610) 825-6000, ext. 5118; by e-mail at tbrowne@ecri.org; or by fax at (610) 834-1275.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.